DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells

Cancer Immunology, Immunotherapy

Volumn 62, Issue 10, 2013, Pages 1619-1628

  Koshio, Jun ^a   Kagamu, Hiroshi ^a   Nozaki, Koichiro ^a   Saida, Yu ^a   Tanaka, Tomohiro ^a   Shoji, Satoshi ^a   Igarashi, Natsue ^a   Miura, Satoru ^a   Okajima, Masaaki ^a   Watanabe, Satoshi ^b   Yoshizawa, Hirohisa ^b   Narita, Ichiei ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

Cancer stem cells; DDX3X; Helper T cells; Tumor immunology

Indexed keywords

CANCER VACCINE; CD133 ANTIGEN; DDX3X PEPTIDE; GAMMA INTERFERON; INTERLEUKIN 17; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD; DEAD-BOX RNA HELICASES; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES;

EID: 84885867020     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1467-x     Document Type: Article

References (29)

1. Li Y, Laterra J (2012) Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 72:576-580. doi: 10.1158/0008-5472.CAN-11-3070
2. Sharma SV, Lee DY, Li B et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69-80. doi: 10.1016/j.cell.2010.02.027
3. Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008-3017. doi: 10.1634/stemcells.2008-0601
4. Milas L, Raju U, Liao Z, Ajani J (2005) Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32:S78-S81. doi: 10.1053/j.seminoncol.2005.04.028
5. Diehn M, Clarke MF (2006) Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98:1755-1757. doi: 10.1093/jnci/djj505
6. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320-4333. doi: 10.1158/0008-5472.CAN-04-3327
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760. doi: 10.1038/nature05236
8. Malanchi I, Peinado H, Kassen D et al (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452:650-653
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115. doi: 10.1038/nature05384
10. Kagamu H, Shu S (1998) Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 160:3444-3452
11. Fujita N, Kagamu H, Yoshizawa H et al (2001) CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 167:5678-5688
12. Miyabayashi T, Kagamu H, Koshio J et al. (2011) Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor. Cancer Immunol Immunother. doi: 10.1007/s00262-011-1063- x
13. Lahn BT, Page DC (1997) Functional coherence of the human Y chromosome. Science 278:675-680
14. Pugh TJ, Weeraratne SD, Archer TC et al (2012) Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488:106-110. doi: 10.1038/nature11329
15. Stransky N, Egloff AM, Tward AD et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160. doi: 10.1126/science.1208130
16. Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365:2497-2506. doi: 10.1056/NEJMoa1109016
17. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, Gejyo F, Yoshizawa H (2005) Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175:5058-5066
18. Watanabe S, Kagamu H, Yoshizawa H, Fujita N, Tanaka H, Tanaka J, Gejyo F (2003) The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 171:5828-5836
19. Botlagunta M, Vesuna F, Mironchik Y et al (2008) Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 27:3912-3922. doi: 10.1038/onc.2008.33
20. Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H (2011) Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer. Clin Cancer Res 17:1895-1905. doi: 10.1158/1078-0432.CCR-10-2316
21. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH (2006) DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res 66:6579-6588. doi: 10.1158/0008-5472.CAN-05-2415
22. Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. doi: 10.1016/j.cell.2008.03.027
23. Sun M, Song L, Zhou T, Gillespie GY, Jope RS (2011) The Role of DDX3 in regulating snail. Biochim Biophys Acta. doi: 10.1016/j.bbamcr.2011.01.003
24. Fan X, Eberhart CG (2008) Medulloblastoma stem cells. J Clin Oncol 26:2821-2827. doi: 10.1200/JCO.2007.15.2264
25. Rosinski KV, Fujii N, Mito JK et al (2008) DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood 111:4817-4826. doi: 10.1182/blood-2007-06-096313
26. Porcheray F, Miklos DB, Floyd BH et al (2011) Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation 92:359-365. doi: 10.1097/TP.0b013e3182244cc3
27. Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, Antin JH, Ritz J (2004) Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 199:1133-1142. doi: 10.1084/jem.20031560
28. Miklos DB, Kim HT, Zorn E et al (2004) Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103:353-359
29. Vogt MH, van den Muijsenberg JW, Goulmy E et al (2002) The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 99:30273032